| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 02/27/2003 | US20030040512 Pharmaceutical composition with protective action against oxidative/toxic substances, especially cardiotoxic substances |
| 02/27/2003 | US20030040510 Selective estrogen receptor modulators in combination with estrogens |
| 02/27/2003 | US20030040509 Methods and compositions for treating diseases associated with excesses in ACE |
| 02/27/2003 | US20030040504 For removing mammalian ectoparasites and/or their eggs |
| 02/27/2003 | US20030040502 Inosine compounds and their use for treating or preventing an inflamation or a reperfusion disease |
| 02/27/2003 | US20030040492 Carbohydrate formulation (prebiotic adjuvant) for enhancement of immune response |
| 02/27/2003 | US20030040490 Drugs containing combined active ingredients |
| 02/27/2003 | US20030040486 Alternating intrathecal administration to the mammal of a pharmaceutically effective dose of opioid receptor agonist for first period of time, and dose of at least one opioid receptor-like receptor 1 agonist for a second period of time |
| 02/27/2003 | US20030040484 Administering a therapeutically-effective amount of an angiotensin converting enzyme inhibitor and administering an aldosterone antagonist to reduce the death rate or the number of non-fatal hospitalizations |
| 02/27/2003 | US20030040464 Method of treating or preventing attention defecit hyperactivity disorder |
| 02/27/2003 | US20030040461 Providing a cell expressing Bruton's Tyrosine Kinase; contacting cell expressing Bruton's Tyrosine Kinase with a test compound; determining whether test compound modulates the activity of Bruton's Tyrosine Kinase |
| 02/27/2003 | US20030040112 Materials and methods for nerve grafting, selection of nerve grafts, and in vitro nerve tissue culture |
| 02/27/2003 | US20030040111 Differentiated cells suitable for human therapy |
| 02/27/2003 | US20030040046 Netrin receptors |
| 02/27/2003 | US20030040044 Anti-dual integrin antibodies, compositions, methods and uses |
| 02/27/2003 | US20030039999 B7 related protein-2 molecules and uses thereof |
| 02/27/2003 | US20030039987 Defects in periaxin associated with myelinopathies |
| 02/27/2003 | US20030039959 Detection of premature tumor cells in mammary gland tissue; obtain mammary gland tissue, incubate with diagnostic agent, monitor sample for binding and signal, presence of signal indicates premature cancer |
| 02/27/2003 | US20030039704 Dermatological preparations |
| 02/27/2003 | US20030039697 Matrices containing nitric oxide donors and reducing agents and their use |
| 02/27/2003 | US20030039691 Compression coatings |
| 02/27/2003 | US20030039689 Prodrug in polymer matrix; insertion into body |
| 02/27/2003 | US20030039687 Using Carbomer |
| 02/27/2003 | US20030039686 Increased absorption; aqueous solution containing fatty acid, or salt thereof |
| 02/27/2003 | US20030039684 Preparation of a directly mouldable tabletting auxiliary |
| 02/27/2003 | US20030039669 Use of a composition containing an effective quantity of at least one chelating agent for partially or totally reducing the symptoms associated with histamine release in the organism |
| 02/27/2003 | US20030039654 Amino acid sequence of parathyroid hormone/parathyroid hormone related protein modulating domains and a vehicle for to stimulate renal calcium reabsorption |
| 02/27/2003 | US20030039628 Treating cancer or viral diseases for enhancing T-cell proliferation by administering an effective amount compound that inhibits the production or release of intercellular reactive oxygen metabolites |
| 02/27/2003 | US20030039627 Administering to the patient a therapeutically effective amount of an amine containing polymer |
| 02/27/2003 | US20030039614 Expanding the homogeneous solution by exposing it to a change in pressure under conditions such that the solution or homogeneous dispersion does not boil |
| 02/27/2003 | US20030039611 Selectively binds to antigen to cause cell impairment |
| 02/27/2003 | DE20219661U1 Composition for treating obesity and reducing cholesterol levels, comprising low-esterified polysaccharide and swellable material |
| 02/27/2003 | CA2459692A1 Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds |
| 02/27/2003 | CA2459434A1 Intravaginal administration of an aromatase inhibitor for the treatment of oestrogen-dependent proliferative disorders |
| 02/27/2003 | CA2458648A1 Secreted proteins |
| 02/27/2003 | CA2458643A1 Nucleic-acid associated proteins |
| 02/27/2003 | CA2458625A1 Transporters and ion channels |
| 02/27/2003 | CA2457932A1 Sodium channel regulators and modulators |
| 02/27/2003 | CA2457745A1 Combination therapy for the treatment of cancer |
| 02/27/2003 | CA2457611A1 Novel molecular target for neurotoxicity |
| 02/27/2003 | CA2457461A1 Complement pathway inhibitors binding to c5 and c5a without preventing the formation of c5b |
| 02/27/2003 | CA2457453A1 Compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and glucosamine |
| 02/27/2003 | CA2457452A1 Compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and chondroitin sulfate |
| 02/27/2003 | CA2457405A1 Compositions and methods relating to benzodiazepine compounds |
| 02/27/2003 | CA2457321A1 Combinatorial methods for inducing cancer cell death |
| 02/27/2003 | CA2457148A1 Treatment of cancers by inhalation of stable platinum-containing formulations |
| 02/27/2003 | CA2457041A1 Novel combination |
| 02/27/2003 | CA2457037A1 Aminoalkyl-substituted aromatic bicyclic compounds, method for the production thereof and their use as medicaments |
| 02/27/2003 | CA2456983A1 Adjuvant chemotherapy for anaplastic gliomas |
| 02/27/2003 | CA2456966A1 Lipidated glycosaminoglycan particles and their use in drug and gene delivery for diagnosis and therapy |
| 02/27/2003 | CA2456820A1 Physiological method of improving vision |
| 02/27/2003 | CA2456746A1 Method for treating lung cancers |
| 02/27/2003 | CA2456470A1 Interleukin-2 mutants with reduced toxicity |
| 02/27/2003 | CA2456292A1 Novel virus growth inhibitor and/or virucidal method, and novel pyrazine nucleotide or pirazine nucleoside analog |
| 02/27/2003 | CA2455827A1 Materials and methods for nerve grafting comprising degrading chondroitin sulfate proteoglycan |
| 02/27/2003 | CA2455120A1 Method and intra sclera implant for treatment of glaucoma and presbyopia |
| 02/27/2003 | CA2454083A1 Use of bibn4096 in combination with other antimigraine drugs for the treatment of migraine |
| 02/27/2003 | CA2423025A1 New dipeptidyl peptidase iv inhibitors and their uses for lowering blood pressure levels |
| 02/26/2003 | WO2002000208A2 Combination preparations of 3-n-formylhydroxylaminopropyl phosphonic acid derivatives or 3-n-acetylhydroxylaminopropyl phosphonic acid derivatives combined with specific pharmaceutical active agents |
| 02/26/2003 | EP1286165A2 Neuropeptide receptor and uses thereof |
| 02/26/2003 | EP1285964A2 Human Mater proteins |
| 02/26/2003 | EP1285947A1 Antimicrobial composition |
| 02/26/2003 | EP1285927A2 Use of glucocorticoid antagonists for the prevention and treatment of diseases of the male reproductive system |
| 02/26/2003 | EP1285658A2 Treatments for female sexual dysfunction |
| 02/26/2003 | EP1285650A1 Method and compositions for inhibiting arteriosclerosis |
| 02/26/2003 | EP1285270A2 Method for identifying compounds for modulating the activity of a tumour suppressor protein |
| 02/26/2003 | EP1285269A2 Lipid uptake assays |
| 02/26/2003 | EP1285092A2 Methods for drug discovery, disease treatment, and diagnosis using metabolomics |
| 02/26/2003 | EP1285087A2 Enzymatic assays for screening anti-cancer agents |
| 02/26/2003 | EP1285074A1 Rh116 polypeptides and its fragments and polynucleotides encoding said polypeptides and therapeutic uses |
| 02/26/2003 | EP1285002A2 REGULATING LIPID LEVELS VIA THE i ZMAX1 /i OR i HBM /i GENE |
| 02/26/2003 | EP1285001A1 Methods for identifying modulators of the interaction between lap (latency associated peptide) and integrin alpha.v.beta.3 and medical use thereof |
| 02/26/2003 | EP1284999A2 Repair of nerve damage |
| 02/26/2003 | EP1284997A2 Therapeutic compounds for ovarian cancer |
| 02/26/2003 | EP1284753A2 Combination of growth hormone secretagogues and antidepressants |
| 02/26/2003 | EP1284750A1 Pharmaceutical composition |
| 02/26/2003 | EP1284749A2 Use of hyaluronidase for preventing and treating cardio vascular diseases |
| 02/26/2003 | EP1284747A2 Compositions and methods for achieving immune suppression |
| 02/26/2003 | EP1284736A2 Opioid antagonist compositions and dosage forms |
| 02/26/2003 | EP1284735A1 Apomorphine derivatives and methods for their use |
| 02/26/2003 | EP1284731A1 Use of compounds having combined dopamine d2, 5-ht1a and alpha adrenoreceptor agonistic action for treating cns disorders |
| 02/26/2003 | EP1284730A1 Aralkyl ester soft drugs |
| 02/26/2003 | EP1284729A1 A(beta)42 lowering agents |
| 02/26/2003 | EP1284728A1 Pharmaceuticals for treating obesity |
| 02/26/2003 | EP1284724A1 Method of preparing alkylated salicylamides via a dicarboxylate intermediate |
| 02/26/2003 | EP1284723A1 Compositions and therapies for hyperlipidaemia-associated disorders |
| 02/26/2003 | EP1284721A2 Compositions and methods for use against acne-induced inflammation and dermal matrix-degrading enzymes |
| 02/26/2003 | EP1284720A2 Method of treating hepatitis delta viral infection |
| 02/26/2003 | EP1284719A2 The use of a calcium channel blocker for treating renal disorders |
| 02/26/2003 | EP1284698A1 Method of pre-selecting a polymerizable fluid formed into an intraocular lens |
| 02/26/2003 | EP1212453A4 Method to identify gene function using small molecule probes |
| 02/26/2003 | EP1143952B1 Method and composition for treating and preventing tuberculosis |
| 02/26/2003 | EP1052998A4 Compositions and methods for modulating cytokine release in response to genotoxic agents |
| 02/26/2003 | EP1011726B1 Fused imidazole derivatives for improving oral bioavailability of pharmaceutical agents |
| 02/26/2003 | EP0938483B1 Muscarinic antagonists |
| 02/26/2003 | EP0799055B1 Selective and non-invasive visualization or treatment of vasculature |
| 02/26/2003 | EP0655914B1 Use of Histamine-2 agonists for treatment of sexual dysfunction |
| 02/26/2003 | EP0436717B1 System for use in a method of therapeutic or diagnostic treatment |
| 02/26/2003 | CN1399678A Human Enzymes of metalloprotease family |
| 02/26/2003 | CN1399644A Novel human G-Protein coupled receptor |